Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Smith & Nephew plc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.17 (market cap $12.87B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Smith & Nephew plc for 121 Days on average.
| EMB | SNN | |
|---|---|---|
Market Cap | $12.87B | $11.10B |
Volume | 14,946,002 | 1,051,703 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $37.17 |
52-Week Low | $90.14 | $26.42 |
Typical Hold Time | 51 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.17, showing modest daily gains of 0.43% amid a bearish technical outlook with 14 sell signals versus 6 buy signals. The stock faces resistance at $91-92 levels while maintaining dividend distributions, though key valuation metrics remain unavailable for fundamental assessment. Recent market commentary suggests limited near-term upside potential.
The outlook remains cautious with technical indicators signaling bearish momentum and Seeking Alpha maintaining a HOLD rating as of July 23, 2026. Primary investment appeal centers on income generation through dividends, though price appreciation appears constrained. Risks include broader market volatility and emerging market bond yield fluctuations affecting fixed-income alternatives.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
